CAPR Evp, General Counsel Karen Krasney Buys $1.3K of Stock
Karen Krasney, EVP and General Counsel at Capricor Therapeutics, bought 400 shares on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Karen Krasney, EVP, GENERAL COUNSEL at Capricor Therapeutics, Inc. ($CAPR), bought 400 shares at an average price of $3.18, worth about $1,272, on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CAPR is down 21.8% after 1 week, down 33.2% after 1 month and down 77.3% to date (from the $29.51 close on Jun 24, 2026).
CAPR
Capricor Therapeutics, Inc.
Key Points
- Karen Krasney purchased 400 shares of Capricor Therapeutics for about $1,272 on June 24, 2026, at an average price of $3.18 per share.
- This buy comes as the stock trades around $29.51, significantly above its 52-week low of $2.96, indicating a recent rise in share price.
- Krasney now holds a total of 24,100 shares, reflecting her ongoing commitment to the company amid recent insider trades.
Get $CAPR trade alerts by text
We text you when insiders, Congress or big funds trade $CAPR. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Capricor Therapeutics, Inc. alert may contain errors. Disclosures
Krasney Buys Shares of Capricor Therapeutics
On June 24, 2026, Karen Krasney, the EVP and General Counsel at Capricor Therapeutics, Inc. (NasdaqGS: CAPR), bought 400 shares valued at approximately $1,272. The purchase was made at an average price of $3.18 per share. This transaction adds to her existing stake in the company.
What's New in Krasney's Position
This recent buy brings Krasney's total holdings to 24,100 shares. Her purchase signals continued confidence in Capricor's future, especially after selling shares just days prior.
Recent Insider Activity
Krasney isn't the only insider making moves at Capricor. On June 25, 2026, CFO Anthony Bergmann bought 24,100 shares for about $76,638, showing his belief in the company's potential. He also sold shares on June 22 and June 24, indicating a mix of trading activity.
How Capricor Therapeutics, Inc. Stock Has Traded
Currently, Capricor Therapeutics shares are trading at $29.51, significantly higher than the 52-week low of $2.96. The stock has seen considerable volatility, climbing from lower levels recently. Investors will be watching how these insider trades affect market sentiment.
Analysts Set New Price Targets
Analysts have been active recently as well. On September 14, 2026, B. Riley Securities upgraded the stock to a Buy rating with a target price of $21. Piper Sandler also upgraded its rating to Overweight with a target of $25 on September 1, 2026. This reflects a generally positive outlook on the stock despite some downgrades in late July.
What Capricor Therapeutics, Inc. Does
Capricor Therapeutics is a clinical-stage biotechnology company based in San Diego, California. It focuses on developing innovative therapies, particularly for Duchenne muscular dystrophy (DMD) and other serious diseases. The recent insider purchases may suggest confidence in the company's ongoing projects and clinical trials.
What's Ahead for Capricor Therapeutics, Inc.
As Capricor prepares for its next earnings report on November 10, 2026, investors will be keen to see how the company's developments unfold. The recent insider trading activity, particularly Krasney's purchases, will likely be a point of interest for market watchers. Remember, the recent 13F filing reflects past positions and may not represent current holdings.
Related Filing Alerts
Source: Karen Krasney's Form 4 filing on $CAPR (Jun 24, 2026). Find the original filing: CAPR Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts